Although she "failed" Arimidex in adjuvant, and her HER2 status is questionable, every biopsy(primary, surgery,liver met) shows her strongly ER+, somewhat PR+.
Just want her to use whatever makes sense. I would love to see a breakdown of the various chemos and responses based on receptor(s). It seems like ER/chemo discussions lump all the chemos together even though they are known to have different mechanisms. I always thought that was probably too simplistic. This old abstract seems to suggest there's more to it. I mean..89% response in any chemo is pretty amazing...even more so in ER+. It seems totally inverted relative to current thinking. Maybe it's just a lousy study and the results are worthless. But what if it's legit? Did the shift to different drugs over the years reduce the effectiveness of "chemo" in ER+? I notice Kerbel is using this drug a lot for
metronomic study. I figured it was just because it's available in oral form. It's just weird because it seems to be viewed as an outdated old school drug.
I am firmly in the camp of "whetever works". Some think different endocrine therapy is better in an ER+/her2 neg recurrence. But maybe that's because certain chemos aren't even looked at/studied anymore. Just don't want options ignored because they have become unfashionable.
When posting to Adrien's thread, I realized I am unaware of any ER+ mets gals getting to NED through chemo.
Threaded Mode